AMSTERDAM — For patients with diffuse cutaneous systemic sclerosis, an autoimmune disease for which there are few treatment options, lenabasum (JBT-101, Corbus Pharmaceuticals) shows potential, new ...

ATLANTA - New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, found no clear association between immunosuppressive or anti-fibrotic ...

The "Systemic Scleroderma Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Regions; Segment Forecast, 2021-2028" report has been added to ResearchAndMarkets.com’s ...

CARLSBAD, California — In 2003, researchers asked 303 patients with systemic sclerosis (scleroderma) what bothered them most about their disease from an aesthetic standpoint: Orofacial features, such ...

Fibrosis, or the scaring of tissue, occurs in many diseases, and is a central component of systemic sclerosis. There are currently no treatments that can reverse fibrosis and the current treatment ...

The drug tofacitinib was well tolerated among patients with early scleroderma, primarily affecting the protein interferon both in fibroblasts and keratinocytes. Researchers say the drug is safe and ...

SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., announced today the online publication (ahead of print) of the findings from the STAR I trial in Arthritis & Rheumatology Journal, the official journal of ...

As Bob Saget is remembered by his friends and co-stars, one memory that stands out is his commitment to finding a cure for scleroderma, a rare disease for which Saget was the most high-profile ...